Tinea nigra

Terutroban is a thromboxane receptor antagonist that was under development for the secondary prevention of stroke and other thrombotic events. It was developed by the French pharmaceutical company Servier.

Mechanism of Action

Terutroban works by blocking the thromboxane receptor, which is involved in the process of blood clotting. This action helps to prevent the formation of blood clots, which can lead to stroke and other thrombotic events.

Clinical Trials

Terutroban was tested in a large-scale clinical trial called the PERFORM study. This study compared the effectiveness of terutroban with that of aspirin in preventing recurrent stroke or other vascular events. However, the study was stopped early because terutroban was not found to be superior to aspirin.

Side Effects

The most common side effects of terutroban include headache, dizziness, and nausea. In some cases, it can also cause bleeding or bruising.

See Also

• Thromboxane receptor antagonist
• Stroke
• Thrombotic events
• Servier
• Aspirin

References

Tinea nigra Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski